Matthew Josleyn

1.2k total citations
21 papers, 577 citations indexed

About

Matthew Josleyn is a scholar working on Infectious Diseases, Ecology, Evolution, Behavior and Systematics and Global and Planetary Change. According to data from OpenAlex, Matthew Josleyn has authored 21 papers receiving a total of 577 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Infectious Diseases, 9 papers in Ecology, Evolution, Behavior and Systematics and 5 papers in Global and Planetary Change. Recurrent topics in Matthew Josleyn's work include Viral Infections and Vectors (17 papers), Viral Infections and Outbreaks Research (14 papers) and Vector-Borne Animal Diseases (9 papers). Matthew Josleyn is often cited by papers focused on Viral Infections and Vectors (17 papers), Viral Infections and Outbreaks Research (14 papers) and Vector-Borne Animal Diseases (9 papers). Matthew Josleyn collaborates with scholars based in United States, Chile and United Kingdom. Matthew Josleyn's co-authors include Jay W. Hooper, John Ballantyne, Rebecca L. Brocato, Joseph W. Golden, Michael Royals, Connie S. Schmaljohn, Steve Kwilas, Y. Terry Lee, Jeffery L. Miller and Sung‐Ho Goh and has published in prestigious journals such as PLoS ONE, The Journal of Infectious Diseases and Science Translational Medicine.

In The Last Decade

Matthew Josleyn

20 papers receiving 565 citations

Peers

Countries citing papers authored by Matthew Josleyn

Since Specialization

Citations

This map shows the geographic impact of Matthew Josleyn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Josleyn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Josleyn more than expected).

Fields of papers citing papers by Matthew Josleyn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Josleyn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Josleyn. The network helps show where Matthew Josleyn may publish in the future.

Co-authorship network of co-authors of Matthew Josleyn

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Josleyn. A scholar is included among the top collaborators of Matthew Josleyn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Josleyn. Matthew Josleyn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 1 clinical trial of Hantaan and Puumala virus DNA vaccines delivered by needle-free injection 2024 ·npj Vaccines ·Jay W. Hooper, Steven A. Kwilas, Matthew Josleyn, Sarah L. Norris, Jack Hutter, (unknown), Jeffrey Livezey, Kristopher Paolino, Patrick Twomey, Michael Koren, Paul B. Keiser, James E. Moon, (unknown), Jason I. Koontz, (unknown), Nathalie Landry, (unknown)	4
2	Preclinical evaluation of a fully human, quadrivalent-hantavirus polyclonal antibody derived from a non-human source 2024 ·mBio ·Rebecca L. Brocato, Hua Wu, Steven A. Kwilas, (unknown), Matthew Josleyn, Joshua D. Shamblin, Padmanabh Chivukula, Christoph Bausch, Thomas Luke, Eddie J. Sullivan, Jay W. Hooper	1
3	Safety and Immunogenicity of an Andes Virus DNA Vaccine by Needle-Free Injection: A Randomized, Controlled Phase 1 Study 2023 ·The Journal of Infectious Diseases ·Grant Paulsen, Robert W. Frenck, Kay M. Tomashek, Rodolfo Alarcón, (unknown), Ashley A. Lowe, Rebecca L. Brocato, Steve Kwilas, Matthew Josleyn, Jay W. Hooper	8
4	Humoral immunogenicity of a Coronavirus Disease 2019 (COVID-19) DNA vaccine in rhesus macaques (Macaca mulatta) delivered using needle-free jet injection 2023 ·PLoS ONE ·(unknown), Steven A. Kwilas, Matthew Josleyn, Keersten M. Ricks, Jay W. Hooper	0
5	Small animal jet injection technique results in enhanced immunogenicity of hantavirus DNA vaccines 2021 ·Vaccine ·Rebecca L. Brocato, Steven A. Kwilas, Matthew Josleyn, Simon Y. Long, Xiankun Zeng, Casey C. Perley, (unknown), (unknown), Melanie Cohen, Jay W. Hooper	11
6	Broad and potently neutralizing monoclonal antibodies isolated from human survivors of New World hantavirus infection 2021 ·Cell Reports ·(unknown), Natalia A. Kuzmina, Adam J. Ronk, Chad E. Mire, (unknown), Nurgun Kose, Matthew Josleyn, Rachel E. Sutton, (unknown), (unknown), (unknown), Francisca Valdivieso, Thomas G. Ksiazek, Jay W. Hooper, Alexander Bukreyev, James E. Crowe	21
7	Broad and potently neutralizing monoclonal antibodies isolated from human survivors of New World hantavirus infection 2021 ·Cell Reports ·(unknown), Natalia A. Kuzmina, Adam J. Ronk, Chad E. Mire, (unknown), Nurgun Kose, Matthew Josleyn, Rachel E. Sutton, (unknown), (unknown), (unknown), Francisca Valdivieso, Thomas G. Ksiazek, Jay W. Hooper, Alexander Bukreyev, James E. Crowe	3
8	A Phase 2a Randomized, Double-Blind, Dose-Optimizing Study to Evaluate the Immunogenicity and Safety of a Bivalent DNA Vaccine for Hemorrhagic Fever with Renal Syndrome Delivered by Intramuscular Electroporation 2020 ·Vaccines ·Jay W. Hooper, Kristopher Paolino, Kristin T Mills, Steve Kwilas, Matthew Josleyn, Melanie Cohen, (unknown), Marcin Wiśniewski, Sarah L. Norris, Brenna J. Hill, Mariano Sánchez-Lockhart, D. Hannaman, Connie S. Schmaljohn	27
9	Innate immune responses elicited by Sin Nombre virus or type I IFN agonists protect hamsters from lethal Andes virus infections 2018 ·Journal of General Virology ·Rebecca L. Brocato, Victoria Wahl‐Jensen, Christopher Hammerbeck, Matthew Josleyn, Anita K. McElroy, Jeffrey M. Smith, Jay W. Hooper	4
10	Human polyclonal antibodies produced in transchromosomal cattle prevent lethal Zika virus infection and testicular atrophy in mice 2017 ·Antiviral Research ·Derek R. Stein, Joseph W. Golden, Bryan D. Griffin, Bryce M. Warner, Charlene Ranadheera, (unknown), Angela Sloan, Kathy L. Frost, Darwyn Kobasa, Stephanie A. Booth, Matthew Josleyn, John Ballantyne, Eddie J. Sullivan, Jin‐an Jiao, Hua Wu, Zhongde Wang, Jay W. Hooper, David Safronetz	20
11	Antiviral Biologic Produced in DNA Vaccine/Goose Platform Protects Hamsters Against Hantavirus Pulmonary Syndrome When Administered Post-exposure 2015 ·PLoS neglected tropical diseases ·Nicole N. Haese, Rebecca L. Brocato, (unknown), Matthew L. Nilles, Steve Kwilas, Matthew Josleyn, Christopher Hammerbeck, (unknown), Michael Royals, John Ballantyne, Jay W. Hooper, David S. Bradley	39
12	A Hantavirus Pulmonary Syndrome (HPS) DNA Vaccine Delivered Using a Spring-powered Jet Injector Elicits a Potent Neutralizing Antibody Response in Rabbits and Nonhuman Primates 2014 ·Current Gene Therapy ·Steve Kwilas, (unknown), Matthew Josleyn, (unknown), John Ballantyne, Michael Royals, Jay W. Hooper	45
13	A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for haemorrhagic fever with renal syndrome delivered by intramuscular electroporation 2014 ·Clinical Microbiology and Infection ·Jay W. Hooper, James E. Moon, Kristopher Paolino, (unknown), (unknown), Matthew Josleyn, D. Hannaman, Connie S. Schmaljohn	50
14	DNA vaccine–derived human IgG produced in transchromosomal bovines protect in lethal models of hantavirus pulmonary syndrome 2014 ·Science Translational Medicine ·Jay W. Hooper, Rebecca L. Brocato, Steven A. Kwilas, Christopher Hammerbeck, Matthew Josleyn, Michael Royals, John Ballantyne, Hua Wu, Jin‐an Jiao, Hiroaki Matsushita, Eddie J. Sullivan	49
15	A novel Sin Nombre virus DNA vaccine and its inclusion in a candidate pan-hantavirus vaccine against hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS) 2013 ·Vaccine ·Jay W. Hooper, Matthew Josleyn, John Ballantyne, Rebecca L. Brocato	46
16	A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome 2012 ·Vaccine ·Ellen F. Boudreau, Matthew Josleyn, Diane E. Ullman, Diana Fisher, (unknown), (unknown), Peter T. Loudon, Janice M. Rusnak, Robert G. Rivard, Connie S. Schmaljohn, Jay W. Hooper	47
17	DNA Vaccine-Generated Duck Polyclonal Antibodies as a Postexposure Prophylactic to Prevent Hantavirus Pulmonary Syndrome (HPS) 2012 ·PLoS ONE ·Rebecca L. Brocato, Matthew Josleyn, John Ballantyne, Pablo Vial, Jay W. Hooper	44
18	Side-by-Side Comparison of Gene-Based Smallpox Vaccine with MVA in Nonhuman Primates 2012 ·PLoS ONE ·Joseph W. Golden, Matthew Josleyn, Eric M. Mucker, Chien‐Fu Hung, Peter T. Loudon, T.‐C. Wu, Jay W. Hooper	31
19	Development and application of a flow cytometric potency assay for DNA vaccines 2011 ·Vaccine ·Catherine V. Badger, (unknown), (unknown), Michelle J. Richards, Matthew Josleyn, Lesley C. Dupuy, Jay W. Hooper, Connie S. Schmaljohn	13
20	Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies 2008 ·Vaccine ·Joseph W. Golden, Matthew Josleyn, Jay W. Hooper	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact